Helical Raises $10M for AI Drug Discovery Platform

Helical, a nascent biotechnology firm, has successfully closed a $10 million seed funding round to accelerate the development of its sophisticated virtual laboratory powered by artificial intelligence. This significant capital infusion, spearheaded by redalpine, with crucial participation from Gradient, BoxGroup, and Frst, alongside notable angel investors including Aidan Gomez (CEO of Cohere) and Clement Delangue (CEO of Hugging Face), signals strong market confidence in Helical's approach to revolutionizing pharmaceutical R&D.

The company's core innovation addresses a critical bottleneck in the drug discovery pipeline: the laborious and time-consuming nature of physical experimentation. While advanced biological foundation models offer powerful computational hypothesis testing, translating these digital insights into reproducible, actionable scientific workflows has remained a persistent challenge for many pharmaceutical research teams. Helical's platform acts as an essential application layer, bridging the gap between raw AI model outputs and validated, decision-ready research protocols.

Founded in early 2024 by Rick Schneider, Maxime Allard, and Mathieu Klop, Helical's virtual AI lab is engineered to transform complex biological foundation models into robust, repeatable in-silico discovery systems. The platform is architected with two integrated components: the 'Virtual Lab,' designed for biologists and translational scientists, and the 'Model Factory,' catering to machine learning engineers and data scientists. By enabling these teams to operate on shared data, models, and experimental results, Helical fosters unprecedented collaboration across traditionally siloed departments, driving evidence-based decision-making throughout the entire discovery lifecycle.

“Meaningful drug discovery is driven by systems that combine and operationalize model insights, not by models alone,” stated Rick Schneider, co-founder of Helical. “Pharmaceutical teams require a system that transforms foundation models into workflows that scientists can readily execute, validate, and defend. We established Helical to enable in-silico science to achieve reproducibility at pharmaceutical scale, drastically reducing the time from hypothesis to decision from months to mere days.”

Helical is already engaging with several of the world's top-20 pharmaceutical giants, demonstrating the platform's immediate applicability across critical areas such as target identification, biomarker discovery, and therapeutic design. Early deployments have already shown substantial reductions in discovery timelines and facilitated the exploration of new therapeutic avenues, underscoring the platform's potential to reshape R&D efficiency in a sector grappling with escalating costs and extended development cycles. The global pharmaceutical R&D spending is projected to exceed $200 billion annually, making innovations that enhance efficiency particularly valuable.

The newly acquired capital will be strategically deployed to deepen existing client engagements within various therapeutic areas, expand outreach to a broader range of pharmaceutical organizations, and further enhance the platform's 'evidence layer.' This focus on strengthening the evidence layer aims to continuously improve performance and reliability across diverse disease indications, solidifying Helical's position as a key enabler of next-generation drug discovery.